Navigation Links
Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
Date:10/21/2008

LAUSANNE, Switzerland, October 21 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today that the first healthy elderly subjects have been randomised in a clinical bioequivalence bridging study, conducted in the United States under IND (Investigational New Drug).

This study aims to compare the tolerability, safety and pharmacokinetic profiles of a single dose of two different Debio 9902 tablet formulations in healthy elderly subjects. This open label, randomized, crossover bioequivalence bridging study seeks to compare a new tablet formulation with the one used in the Phase IIb BRAINz trial (Better Recollection for Alzheimer's patients with the ImplaNt of ZT-1), which has now completed patient enrolment.

"Our primary objective is to provide a safe, comfortable and effective treatment for Alzheimer patients and the initiation of this bioequivalence trial brings us one step closer to our goal," said Kamel Besseghir, CEO of Debiopharm S.A. "Indeed, prior to receiving the Debio 9902 SR monthly implant, patients will receive the oral tablet formulation during a run-in period. The new tablet formulation will provide enhanced stability necessary to meet market requirements."

About Debio 9902 SR (ZT-1)

Debio 9902 SR is a novel acetylcholinesterase (AChE) inhibitor, administered monthly. It is transformed non-enzymatically into its active compound, huperzine A (hup A). Hup A has been used in China for centuries to treat distinct disorders such as memory loss, schizophrenia and hypertension, and is widely used in North America and Europe as a food additive to enhance cognition and neuroprotection. In addition to the inhibition of acetylcholinesterase by Debio 9902 SR, its potential neuroprotective effects as an N-methyl-D-aspartate receptor antagonist position this product as a third generation treatment for Alzheim
'/>"/>

SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
2. Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System
3. CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. First Town Hall Meeting on Inequities in Clinical Trials to Take Place at the Harlem Hospital Center on October 20
6. Perceptive Informatics Improves Clinical Trial Management With Enhanced TrialWorks(R) Solution
7. Insmed Initiates Clinical Study for Follow-on Biologic Version of Neulasta(R)
8. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
9. Paratek to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
10. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
11. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HILL, S.C. , Sept. 18, 2014   3D ... addition of the Simbionix RobotiX Mentor™ , a new ... shown for the first time at the ERUS exhibition in ... to 19 (booth #7). Robotic-assisted minimally invasive surgery ... increased demand means the needs for training for robotic surgery ...
(Date:9/18/2014)... , Sept. 18, 2014 Veterinary biologic ... Dr. Ashraf Hanna , M.D., Ph.D., and Dr. ... of Directors. Dr. Hanna is the Vice President of ... Financial Officer for the Genentech Foundation, while Dr. McCracken ... of Business Development and Licensing for Roche Pharma. ...
(Date:9/18/2014)... Mass. , Sept. 18, 2014  Spring ... novel therapeutics for the treatment of RNA viruses, ... Institutes of Health (NIH) for animal testing of ... viral pathogens, classified as "Special Pathogens," against which ... 9200, derived from Spring Bank,s proprietary ...
Breaking Medicine Technology:3D Systems Introduces New Simbionix Robotics Training Platform 23D Systems Introduces New Simbionix Robotics Training Platform 3Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... MYRTLE BEACH, S.C., Sept. 19, 2011 Laser ... has received an FDA approval for its revolutionary laser ... treats pain through nerve tissue regeneration. ... trigeminal nerve in the face. The trigeminal nerve (the ...
... 19, 2011 Bayer HealthCare, one of the world,s ... to support the Women,s International Leadership (WIL) Program at ... that Bayer HealthCare has established as part of its ... to further develop an environment that fosters the development ...
Cached Medicine Technology:FDA Approved, Non-Invasive Laser Is A Success in Trigeminal Neuralgia Pain Treatment 2International House and Bayer HealthCare Partner to Prepare Women for Leadership Positions 2International House and Bayer HealthCare Partner to Prepare Women for Leadership Positions 3
(Date:9/18/2014)... 2014 Limited spots remain at Becker's ... 100 spots are still available for Becker's ASC 21st ... on October 23-25, 2014 at the Swissotel Chicago. , ... Information Officer Strategy Roundtable on November 4, 2014 at ... for Becker's Hospital Review Chief Executive Officer Strategy Roundtable ...
(Date:9/18/2014)... Angeles, CA (PRWEB) September 18, 2014 ... manufacture and refine carbon dioxide, selling it to downstream ... largest markets for carbon dioxide are food and beverage ... products, such as fruits, vegetables or pizzas. The gas ... Beverage manufacturers use the compound to carbonate soft drinks, ...
(Date:9/18/2014)... Amy Norton HealthDay Reporter , ... dose of a common antidepressant can quickly alter the way ... The findings, reported online Sept. 18 in Current ... response to widely prescribed antidepressants. Experts said the hope is ... are likely to benefit from a drug -- and which ...
(Date:9/18/2014)... Chest Physicians (CHEST) together with the Chinese Thoracic ... of CTS that CHEST World Congress 2016 will ... critical care, and sleep medicine from around the ... slated for spring 2016. , CHEST World ... hands-on simulation training, keynote addresses, presentations by leading ...
(Date:9/18/2014)... Thousands of college and high school ... fundraising impact on 127 member Children’s Miracle Network ... Dance Marathon Day will officially kick off a school ... raised by college and high school students funding vital ... Dance Marathon campus programs help provide medical equipment, treatment ...
Breaking Medicine News(10 mins):Health News:Limited Spots Remain at Becker's Upcoming ASC and Hospital Conferences 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3Health News:CHEST announces China as site of CHEST World Congress 2016 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2
... ShopAtHome.com, a leading Free Coupon and Cash Back ... 1, 2009 to help shoppers shop, save, and donate! ... Komen for the Cure® as part of a month-long ... http:// href="http://www.newscom.com/cgi-bin/prnh/20091001/LA85003LOGO"> www.newscom.com/cgi-bin/prnh/20091001/LA85003LOGO ) , ...
... CITY, Mo., Oct. 1 DST Systems, Inc. (NYSE: ... Company has entered into separate privately negotiated exchange agreements ... principal of the Company,s outstanding 4.125% Series A Convertible ... in aggregate principal of new 4.125% Series C Convertible ...
... recent study published in the October 2009 issue of the ... specific genetic markers identified in previous research, or SNPs, may ... in whites. The genes CHRNA3 and CHRNA5 may contribute to ... nicotine dependence. Although their presence is less frequent in African ...
... Many patients urgently admitted to hospital with cerebral infarction ... prolonged period prior to suffering their stroke, is shown ... the Sahlgrenska Academy at the University of Gothenburg and ... published in the scientific journal BMC Medicine . ...
... they get less sleep than they actually do, study finds ... longer and better than older men, even though many women ... found. , The study of 956 people, aged 59 to ... men on all of the self-reported measures, including a 13.2 ...
... Attacks New York Department of ,Hype, with New York Times Ad ... (CCF) is running a full-page ad in the New York Times ... Department of Health,s hyperbolic "Don,t drink yourself fat" PSA campaign. The Center ... News and New York Post that ask New Yorkers, ...
Cached Medicine News:Health News:ShopAtHome.com Helps Shoppers Save Money and Support Breast Cancer Research 2Health News:DST Systems, Inc. Announces Exchange Transaction Involving 4.125% Series A Convertible Senior Debentures 2Health News:Lung cancer risk increases with expression of specific genes 2Health News:Severe stress can cause stroke 2Health News:Older Women May Sleep Better Than Men 2Health News:Consumer Group Continues Million Dollar Campaign Responding to NYC Health Officials' Hyperbolic PSA Campaign 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: